# Richard D. Carvajal

Source: https://onco.cc/people/richard-carvajal/  
OnCo record `richard-carvajal` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Melanoma oncologist who led the tebentafusp programme in the United States and defined targeted therapy for rare melanoma subtypes.

## Summary

Richard Carvajal co-led the tebentafusp development programme including the pivotal IMCgp100-202 trial in metastatic uveal melanoma and the early trials of MEK inhibition in uveal melanoma, and led studies of imatinib in KIT-mutant melanoma. He directs medical oncology at Northwell and continues to focus on rare melanoma subtypes.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: uveal-melanoma; rare-cancers
- Role: Deputy Physician-in-Chief and Director of Medical Oncology, Northwell Health Cancer Institute
- Specialisms: Uveal melanoma; Mucosal and acral melanoma; KIT-mutant melanoma; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Carvajal%20RD%5BAuthor%5D%20uveal%20melanoma

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [gp100 (PMEL)](https://onco.cc/targets/gp100/), [KIT](https://onco.cc/targets/kit/)
- drugs: [Imatinib](https://onco.cc/drugs/imatinib/), [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- institutions: [Northwell Health Cancer Institute](https://onco.cc/institutions/northwell-cancer-institute/)
- trials: [IMCgp100-202](https://onco.cc/trials/imcgp100-202/)

---
JSON: https://onco.cc/api/v1/entities/richard-carvajal.json